Exclusive partnership

Exclusive partnership

SCHWIND eye-tech-solutions, Germany, has announced an exclusive partnership with ALPHAEON Corporation, US. SCHWIND has granted ALPHAEON the exclusive license to market SCHWIND AMARIS technology in the US. As part of the relationship, ALPHAEON will oversee and finance the US Food and Drug Administration (FDA) clinical trial required to market the product in the US. ALPHAEON, a wholly-owned subsidiary of Strathspey Crown Holdings LLC, closely cooperates with American eye surgeons to bring highly developed technologies to the US market. SCHWIND chief executive officer Rolf Schwind (pictured) said: “This cooperation is a historical milestone in the SCHWIND company history and for us, as a medium-sized family company, the best possible strategy to establish our cutting-edge technology in North America without entrepreneurial risks. We strongly believe that our partnership with ALPHAEON will build customer confidence and significantly impact the growth of patient procedures.”

www.eye-tech-solutions.com

Latest Articles
ESCRS Today 2025: Happy Anniversaries!

ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.

Read more...

ESCRS Today 2025: A Congress for Everyone

From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.

Read more...

ESCRS Today 2025: All Eyes on Innovation

Watching out for obstacles and opportunities

Read more...

Beyond the Numbers

Empowering patient participation fosters continuous innovation in cataract surgery.

Read more...

Thinking Beyond the Surgery Room

Practice management workshop focuses on financial operations and AI business applications.

Read more...

Aid Cuts Threaten Global Eye Care Progress

USAID closure leads retreat in development assistance.

Read more...

Supplement: ESCRS Clinical Trends Series: Presbyopia

Read more...

Debate: FS-LASIK or KLEx for Hyperopia?

FS-LASIK has more of a track record, but KLEx offers advantages.

Read more...

Four AI Applications Ready for Practice

Commercial offerings may save time, improve practice and research.

Read more...

Perioperative Medication Regimens for Cataract Surgery

Randomised controlled clinical trial results provide evidence-based guidance.

Read more...